Peter Sandner is a pharmacist by training, holds a PhD in Physiology from the University of Regensburg and is an appointed extraordinary professor for pharmacology at Hannover Medical School. Peter is working in Drug Discovery Research of Bayer AG, Pharmaceuticals at the Research Center at Wuppertal, Germany for almost 25 years and was nominated at Chief Scientist in 2016. Within Bayer Peter continued his academic research on cyclic nucleotides and cGMP by nonclinical profiling of cGMP-increasing therapeutic principles, especially phosphodiesterase inhibitors and stimulators and activators of sGC. He is responsible for the nonclinical research with sGC stimulators and sGC activators in various therapeutic areas.

Prof. Cannone is Associate Professor of Internal Medicine at the University of Parma, Parma, Italy, Research Collaborator at the Cardiorenal Research Laboratory at Mayo Clinic, Rochester, MN, USA and Scientific Advisor for E-STAR Biotech Company. Prof. Cannone’s translational research studies have been focused on genetics and cardiometabolic properties of natriuretic peptides. More specifically, Prof. Cannone has analyzed the clinical phenotype and risk associated with genetic variants of natriuretic peptides. In animal model of hypertension and metabolic syndrome, Prof. Cannone has also investigated the cardiovascular and metabolic actions of MANP, which is a novel ANP-like peptide designed at Mayo Clinic. Importantly, funded by the American Heart Association and Mayo Clinic Department of Cardiovascular Medicine, Prof. Cannone has also served as the Principal Investigator in a clinical study focused on evaluating the acute cardiometabolic action of MANP in subjects with hypertension and metabolic syndrome. As Scientific Advisor, Prof. Cannone is currently involved in a phase II clinical trial aimed to test MANP in difficult to control/resistant hypertension. Prof. Cannone has been the recipient of awards from the Heart Failure Society of America and the Italian Society of Arterial Hypertension. Prof. Cannone’s long-term goal is the development of a natriuretic peptide-based therapy for cardiometabolic disease.

Aisah is a Lecturer in Cardiovascular Pharmacology at Queen Mary University of London. She graduated with a BSc (Hons) in Pharmacology before gaining her PhD from King’s College London, under the mentorship of Professor Susan D Brain. Aisah moved to William Harvey Research Institute in 2016 as a postdoctoral research fellow in the lab of Professor Adrian Hobbs. Aisah’s research focuses on studying the role of C-type natriuretic peptide in vascular remodelling and aortic aneurysms. She was the Chair for the IUPHAR ECR Committee (2018-2022). Aisah is a Senior Editor for Pharmacology Matters, BPS Ambassador regional coordinator and member of BPS Engagement Committee.